Last reviewed · How we verify
NCT06794710: EARLY-MYO-RARE
Early Identification and Treatment of Rare Cardiomyopathy Cohorts
NA trial testing diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids in Hypertrophic Cardiomyopathy (HCM) in 300 participants. Not yet recruiting.
30 May 2027
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 300 |
| Start date | 1 February 2025 |
| Primary completion | 30 May 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids — full drug profile →
- Close follow-up
- early rehabilitation guidance
Conditions studied
- Hypertrophic Cardiomyopathy (HCM) — all drugs for Hypertrophic Cardiomyopathy (HCM) →
- Dilated Cardiomyopathy (DCM) — all drugs for Dilated Cardiomyopathy (DCM) →
- Metabolic Cardiomyopathy — all drugs for Metabolic Cardiomyopathy →
- Restrictive Cardiomyopathy — all drugs for Restrictive Cardiomyopathy →
Sponsor
RenJi Hospital
Who can join
Adults 18 to 75, any sex, with Hypertrophic Cardiomyopathy (HCM) or Dilated Cardiomyopathy (DCM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. The investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. In the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. Multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. The effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06794710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertrophic Cardiomyopathy (HCM)
Currently open trials in the same condition.
- NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
- NCT07359690 — Multimodal Analysis of Endomyocardial Biopsies · recruiting
- NCT07344480 — Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM) · recruiting
- NCT06882668 — Role of Cardiovascular Imaging in the Early Diagnosis of Hypertrophic Cardiomyopathy in Women · active not recruiting
- NCT06599229 — Perfusion Abnormalities in Hypertrophic Cardiomyopathy · active not recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06794710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 27 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06794710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing